Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 33-47

  de la Fuente, Josu ^a   Baruchel, André ^b   Biondi, Andrea ^c   de Bont, Eveline ^d   Dresse, Marie Françoise ^e   Suttorp, Meinolf ^f   Millot, Frédéric ^g  

^a St Mary Hospital Medical School   (United Kingdom)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Centre Hospitalier Regional de La Citadelle   (Belgium)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

BCR ABL1; Children; Chronic myeloid leukaemia; Stem cell transplantation; Tyrosine kinase inhibitor

Indexed keywords

ALLOPURINOL; ANTIEMETIC AGENT; BCR ABL PROTEIN; DASATINIB; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; ONDANSETRON; PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; AGE; ANEMIA; ARTICLE; BLAST CELL CRISIS; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER PROGNOSIS; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONGENITAL MALFORMATION; CRYOPRESERVATION; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HLA TYPING; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMMUNOPHENOTYPING; INFECTION; LETHARGY; LEUKOSTASIS; LIVER DYSFUNCTION; LONG TERM CARE; MACULOPAPULAR RASH; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OOCYTE; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PATIENT MONITORING; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SINGLE DRUG DOSE; SPERM PRESERVATION; THROMBOCYTOPENIA; VITRIFICATION; VOMITING; WEIGHT GAIN; ALGORITHM; CHEMISTRY; FEMALE; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION COMPLIANCE; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PROTEIN DOMAIN;

ADOLESCENT; ALGORITHMS; CHILD; CHILD, PRESCHOOL; FEMALE; FUSION PROTEINS, BCR-ABL; GUIDELINE ADHERENCE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; MUTATION; PREGNANCY; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84909980867     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12977     Document Type: Article

References (94)

1. Ali, R., Ozkalemkas, F., Ozkocaman, V., Ozcelik, T., Ozan, U., Kimya, Y. & Tunali, A. (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Japanese Journal of Clinical Oncology, 34, 215-217.
2. Andolina, J.R., Neudorf, S.M. & Corey, S.J. (2012) How I treat childhood CML. Blood, 119, 1821-1830.
3. Aplenc, R., Blaney, S.M., Strauss, L.C., Balis, F.M., Shusterman, S., Ingle, A.M., Agrawal, S., Sun, J., Wright, J.J. & Adamson, P.C. (2011) Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. Journal of Clinical Oncology, 29, 839-844.
4. Apperley, J. (2009a) Issues of imatinib and pregnancy outcome. Journal of the National Comprehensive Cancer Network, 7, 1050-1058.
5. Apperley, J. (2009b) CML in pregnancy and childhood. Best Practice & Research Clinical Haematology, 22, 455-474.
6. Ault, P., Kantarjian, H., O'Brien, S., Faderl, S., Beran, M., Rios, M.B., Koller, C., Giles, F., Keating, M., Talpaz, M. & Cortes, J. (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. Journal of Clinical Oncology, 24, 1204-1208.
7. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. & Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809-1820.
8. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J. & Hehlmann, R. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041-6051.
9. Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D.W., Larson, R.A., Lipton, J.H., Mahon, F.X., Martinelli, G., Mayer, J., Muller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, G., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.L., Goldman, J.M. & Hehlmann, R. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872-884.
10. Bansal, D., Shava, U., Varma, N., Trehan, A. & Marwaha, R.K. (2012) Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatric Blood & Cancer, 59, 481-484.
11. Bashir, Q., de Lima, M.J., McMannis, J.D., Garcia-Manero, G., Shpall, E., Kantarjian, H., Cortes, J.E., O'Brien, S.M., Jones, D., Qazilbash, M., Wei, W., Giralt, S.A., Champlin, R.E. & Hosing, C. (2010) Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia & Lymphoma, 51, 1478-1484.
12. Bixby, D. & Talpaz, M. (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia, 25, 7-22.
13. Bond, M., Bernstein, M.L., Pappo, A., Schultz, K.R., Krailo, M., Blaney, S.M. & Adamson, P.C. (2008) A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric Blood & Cancer, 50, 254-258.
14. Branford, S. & Hughes, T.P. (2011) Mutational analysis in chronic myeloid leukemia: when and what to do? Current Opinion in Hematology, 18, 111-116.
15. Brenner, B., Avivi, I. & Lishner, M. (2012) Haematological cancers in pregnancy. Lancet, 379, 580-587.
16. Burchert, A., Muller, M.C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A. & Hochhaus, A. (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. Journal of Clinical Oncology, 28, 1429-1435.
17. Cawein, M., Lappat, E.J. & Rackley, J.W. (1965) Down's syndrome and chronic myelogenous leukemia. Archives of Internal Medicine, 116, 505-508.
18. Champagne, M.A., Capdeville, R., Krailo, M., Qu, W., Peng, B., Rosamilia, M., Therrien, M., Zoellner, U., Blaney, S.M. & Bernstein, M. (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood, 104, 2655-2660.
19. Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R., Shan, J., Giles, F., Faderl, S., Verstovsek, S., Garcia-Manero, G., Rios, M.B. & Kantarjian, H. (2005) Molecular responses in patients with chronic myeloid leukemia in chronic phase treted with imatinib mesylate. Clinical Cancer Research, 11, 3425-3432.
20. Cortes, J., O'Brien, S., Ault, P., Borthakur, G., Jabbour, E., Bradley-Garelik, B., Debreczeni, K., Yang, D., Liu, D. & Kantarjian, H. (2008) Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. (Abstract). Blood, 112, 1109.
21. Cortes, J.E., Egorin, M.J., Guilhot, F., Molimard, M. & Mahon, F.X. (2009) Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia, 23, 1537-1544.
22. Cross, N.C., White, H.E., Muller, M.C., Saglio, G. & Hochhaus, A. (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 26, 2172-2175.
23. Cwynarski, K., Roberts, I.A., Iacobelli, S., van Biezen, A., Brand, R., Devergie, A., Vossen, J.M., Aljurf, M., Arcese, W., Locatelli, F., Dini, G., Niethammer, D., Niederwieser, D. & Apperley, J.F. (2003) Stem cell transplantation for chronic myeloid leukemia in children. Blood, 102, 1224-1231.
24. De Lavallade, H., Apperley, J.F., Khorashad, J.S., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. & Marin, D. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology, 26, 3358-3363.
25. Deininger, M.W., Cortes, J., Paquette, R., Park, B., Hochhaus, A., Baccarani, M., Stone, R., Fischer, T., Kantarjian, H., Niederwieser, D., Gambacorti-Passerini, C., So, C., Gathmann, I., Goldman, J.M., Smith, D., Druker, B.J. & Guilhot, F. (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer, 110, 1509-1519.
26. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408-2417.
27. Fabarius, A., Leitner, A., Hochhaus, A., Muller, M.C., Hanfstein, B., Haferlach, C., Gohring, G., Schlegelberger, B., Jotterand, M., Reiter, A., Jung-Munkwitz, S., Proetel, U., Schwaab, J., Hofmann, W.K., Schubert, J., Einsele, H., Ho, A.D., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Spiekermann, K., Baerlocher, G.M., Lauseker, M., Pfirrmann, M., Hasford, J., Saussele, S. & Hehlmann, R. (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118, 6760-6768.
28. Fitter, S., Dewar, A.L., Kostakis, P., To, L.B., Hughes, T.P., Roberts, M.M., Lynch, K., Vernon-Roberts, B. & Zannettino, A.C. (2008) Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111, 2538-2547.
29. Giona, F., Mariani, S., Gnessi, L., Moleti, M.L., Rea, M., De, V.A., Marzella, D., Testi, A.M. & Foa, R. (2013) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica, 98, e25-e27.
30. Hanfstein, B., Muller, M.C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A., Schnittger, S., Haferlach, C., Gohring, G., Proetel, U., Kolb, H.J., Krause, S.W., Hofmann, W.K., Schubert, J., Einsele, H., Dengler, J., Hanel, M., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Branford, S., Hughes, T.P., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Saussele, S. & Hochhaus, A. (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096-2102.
31. Hehlmann, R. (2012) How I treat CML blast crisis. Blood, 120, 737-747.
32. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Loffler, H., Hochhaus, A. & Heinze, B. (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84, 4064-4077.
33. Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Muller, M.C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., Hanel, M., Pfirrmann, M., Krause, S.W., Nerl, C., Pralle, H., Gratwohl, A., Hossfeld, D.K., Hasford, J., Hochhaus, A. & Saussele, S. (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. Journal of Clinical Oncology, 29, 1634-1642.
34. Hobernicht, S.L., Schweiger, B., Zeitler, P., Wang, M. & Hunger, S.P. (2011) Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatric Blood & Cancer, 56, 671-673.
35. Hochhaus, A., O'Brien, S.G., Guilhot, F., Druker, B.J., Branford, S., Foroni, L., Goldman, J.M., Muller, M.C., Radich, J.P., Rudoltz, M., Mone, M., Gathmann, I., Hughes, T.P. & Larson, R.A. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23, 1054-1061.
36. Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Baccarani, M., Cortes, J., Cross, N.C., Druker, B.J., Gabert, J., Grimwade, D., Hehlmann, R., Kamel-Reid, S., Lipton, J.H., Longtine, J., Martinelli, G., Saglio, G., Soverini, S., Stock, W. & Goldman, J.M. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, 28-37.
37. Hughes, T.P., Hochhaus, A., Branford, S., Muller, M.C., Kaeda, J.S., Foroni, L., Druker, B.J., Guilhot, F., Larson, R.A., O'Brien, S.G., Rudoltz, M.S., Mone, M., Wehrle, E., Modur, V., Goldman, J.M. & Radich, J.P. (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116, 3758-3765.
38. Ibrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., Mahon, F.X., Kozlowski, K., Paliompeis, C., Foroni, L., Khorashad, J.S., Bazeos, A., Molimard, M., Reid, A., Rezvani, K., Gerrard, G., Goldman, J. & Marin, D. (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 117, 3733-3736.
39. Jaeger, B.A., Tauer, J.T., Ulmer, A., Kuhlisch, E., Roth, H.J. & Suttorp, M. (2012) Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Medical Science Monitor, 18, CR721-CR728.
40. Kantarjian, H., Schiffer, C., Jones, D. & Cortes, J. (2008) Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood, 111, 1774-1780.
41. Kantarjian, H.M., Shan, J., Jones, D., O'Brien, S., Rios, M.B., Jabbour, E. & Cortes, J. (2009) Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. Journal of Clinical Oncology, 27, 3659-3663.
42. Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boque, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M.B., Zhu, C., Szatrowski, T., Shapiro, D. & Baccarani, M. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362, 2260-2270.
43. Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., Wang, J., Ipina, J.J., Kim, D.W., Ogura, M., Pavlovsky, C., Junghanss, C., Milone, J.H., Nicolini, F.E., Robak, T., Van, D.J., Vellenga, E., Bradley-Garelik, M.B., Zhu, C. & Hochhaus, A. (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119, 1123-1129.
44. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F.J., Rosenzweig, A., Salomon, R.N., Van Etten, R.A., Alroy, J., Durand, J.B. & Force, T. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908-916.
45. Khorashad, J.S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J.V., Goldman, J.M., Apperley, J.F. & Kaeda, J. (2006) The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia, 20, 658-663.
46. Khorashad, J.S., de Lavallade, H., Apperley, J.F., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. & Marin, D. (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. Journal of Clinical Oncology, 26, 4806-4813.
47. Klyuchnikov, E., Kroger, N., Brummendorf, T.H., Wiedemann, B., Zander, A.R. & Bacher, U. (2010) Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biology of Blood & Marrow Transplantation, 16, 301-310.
48. Kosenow, W. & Pfeiffer, R.A. (1969) Chronic myeloid leukemia in monozygotic twins. Deutsche Medizinische Wochenschrift, 94, 1170.
49. Krumbholz, M., Karl, M., Tauer, J.T., Thiede, C., Rascher, W., Suttorp, M. & Metzler, M. (2012) Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes & Cancer, 51, 1045-1053.
50. Laneuville, P., Dilea, C., Yin, O.Q., Woodman, R.C., Mestan, J. & Manley, P.W. (2010) Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. Journal of Clinical Oncology, 28, e169-e171.
51. Latagliata, R., Breccia, M., Fava, C., Stagno, F., Tiribelli, M., Luciano, L., Gozzini, A., Gugliotta, G., Annunziata, M., Cavazzini, F., Ferrero, D., Musto, P., Capodanno, I., Iurlo, A., Visani, G., Crugnola, M., Calistri, E., Castagnetti, F., Vigneri, P. & Alimena, G. (2012) Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematological Oncology, 31, 363-369.
52. Lee, S.J., Kukreja, M., Wang, T., Giralt, S.A., Szer, J., Arora, M., Woolfrey, A.E., Cervantes, F., Champlin, R.E., Gale, R.P., Halter, J., Keating, A., Marks, D.I., McCarthy, P.L., Olavarria, E., Stadtmauer, E.A., Abecasis, M., Gupta, V., Khoury, H.J., George, B., Hale, G.A., Liesveld, J.L., Rizzieri, D.A., Antin, J.H., Bolwell, B.J., Carabasi, M.H., Copelan, E., Ilhan, O., Litzow, M.R., Schouten, H.C., Zander, A.R., Horowitz, M.M. & Maziarz, R.T. (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood, 112, 3500-3507.
53. Mahon, F.X., Rea, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 11, 1029-1035.
54. Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J.S., de Lavallade, H., Reid, A.G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., Pavlu, J., Klammer, M., Kaeda, J.S., Goldman, J.M. & Apperley, J.F. (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood, 112, 4437-4444.
55. Marin, D., Khorashad, J.S., Foroni, L., Milojkovic, D., Szydlo, R., Reid, A.G., Rezvani, K., Bua, M., Goldman, J.M. & Apperley, J.F. (2009) Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? British Journal of Haematology, 145, 373-375.
56. Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J.F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., de Lavallade, H., Guallar, C., Goldman, J. & Khorashad, J.S. (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28, 2381-2388.
57. Marin, D., Ibrahim, A.R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R.M., Clark, R.E., Apperley, J.F., Milojkovic, D., Bua, M., Pavlu, J., Paliompeis, C., Reid, A., Rezvani, K., Goldman, J.M. & Foroni, L. (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Clinical Oncology, 30, 232-238.
58. Mauro, M.J. & Deininger, M.W. (2009) Management of drug toxicities in chronic myeloid leukaemia. Best Practice & Research Clinical Haematology, 22, 409-429.
59. Millot, F., Traore, P., Guilhot, J., Nelken, B., Leblanc, T., Leverger, G., Plantaz, D., Bertrand, Y., Bordigoni, P. & Guilhot, F. (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics, 116, 140-143.
60. Millot, F., Guilhot, J., Nelken, B., Leblanc, T., De Bont, E., Becassy, A., Gardner, H., Sufliarska, S., Stary, J., Gschaimeier, H., Guilhot, F. & Suttorp, M. (2006) Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia, 20, 187-192.
61. Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., Mazingue, F., Lutz, P., Vérité, C., Berthoux, C., Galambrun, C., Bernard, F., Yacouben, K., Bordigoni, P., Edan, C., Reguerre, Y., Couillaud, G., Cayuela, J.M. & Guilhot, F. (2009) Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial. (Abstract). Blood, 114, 863.
62. Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., Mazingue, F., Lutz, P., Verite, C., Berthou, C., Galambrun, C., Bernard, F., Yacouben, K., Bordigoni, P., Edan, C., Reguerre, Y., Couillault, G., Mechinaud, F., Cayuela, J.M. & Guilhot, F. (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. Journal of Clinical Oncology, 29, 2827-2832.
63. Muramatsu, H., Kojima, S., Yoshimi, A., Atsuta, Y., Kato, K., Nagatoshi, Y., Inoue, M., Koike, K., Kawase, T., Ito, M., Kurosawa, H., Tanizawa, A., Tono, C., Hamamoto, K., Hotta, N., Watanabe, A., Morishima, Y., Kawa, K. & Shimada, H. (2010) Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biology of Blood & Marrow Transplantation, 16, 231-238.
64. Noens, L., van Lierde, M.A., De, B.R., Verhoef, G., Zachee, P., Berneman, Z., Martiat, P., Mineur, P., Van, E.K., MacDonald, K., De, G.S., Albrecht, T. & Abraham, I. (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 113, 5401-5411.
65. Nurmio, M., Toppari, J., Zaman, F., Andersson, A.M., Paranko, J., Soder, O. & Jahnukainen, K. (2007) Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. International Journal of Andrology, 30, 366-376.
66. Ozer, H., George, S.L., Schiffer, C.A., Rao, K., Rao, P.N., Wurster-Hill, D.H., Arthur, D.D., Powell, B., Gottlieb, A., Peterson, B.A., Rai, K., Testa, J.R., LeBeau, M., Tantravahi, R. & Bloomfield, C.D. (1993) Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood, 82, 2975-2984.
67. Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M. & Mahon, F.X. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109, 3496-3499.
68. Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., Eccersley, L., Hjorth-Hansen, H., Hoglund, M., Klamova, H., Knutsen, H., Parikh, S., Raffoux, E., Gruber, F., Brito-Babapulle, F., Dombret, H., Duarte, R.F., Elonen, E., Paquette, R., Zwaan, C.M. & Lee, F.Y. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112, 1005-1012.
69. Pye, S.M., Cortes, J., Ault, P., Hatfield, A., Kantarjian, H., Pilot, R., Rosti, G. & Apperley, J.F. (2008) The effects of imatinib on pregnancy outcome. Blood, 111, 5505-5508.
70. Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C. & Boschelli, F. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of Clinical Oncology, 27, 469-471.
71. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., Fenaux, P. & Preudhomme, C. (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100, 1014-1018.
72. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M.C. & Loeffler, M. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine, 12, 1181-1184.
73. Saglio, G., Kim, D.W., Issaragrisil, S., Le, C.P., Etienne, G., Lobo, C., Pasquini, R., Clark, R.E., Hochhaus, A., Hughes, T.P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R.A. & Kantarjian, H.M. (2010a) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362, 2251-2259.
74. Saglio, G., Hochhaus, A., Goh, Y.T., Masszi, T., Pasquini, R., Maloisel, F., Erben, P., Cortes, J., Paquette, R., Bradley-Garelik, M.B., Zhu, C. & Dombret, H. (2010b) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer, 116, 3852-3861.
75. Sanz, L., Cervantes, F., Esteve, J., Vilardell, J., Marin, P., Rozman, C. & Montserrat, E. (1996) Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography. Sangre (Barc), 41, 391-393.
76. Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D.W., Bunjes, D., Schwerdtfeger, R., Kolb, H.J., Ho, A.D., Falge, C., Holler, E., Schlimok, G., Zander, A.R., Arnold, R., Kanz, L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, M., Muller, M.C., Schnittger, S., Leitner, A., Pletsch, N., Hochhaus, A., Hasford, J. & Hehlmann, R. (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 115, 1880-1885.
77. Schmid, H., Jäger, B., Lohse, J. & Suttorp, M. (2009) Longitudinal growth retardation in a prepupertal girl with chronic myeloid leukemia on long-term imatinib treatment. Haematologica, 94, 1177-1179.
78. Schultheis, B., Nijmeijer, B.A., Yin, H., Gosden, R.G. & Melo, J.V. (2012) Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leukemia Research, 36, 271-274.
79. Setty, B.A., Hayani, K.C., Sharon, B.I. & Schmidt, M.L. (2009) Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection. Pediatric Blood & Cancer, 53, 658-660.
80. Shah, N.P., Kim, D.W., Kantarjian, H., Rousselot, P., Llacer, P.E., Enrico, A., Vela-Ojeda, J., Silver, R.T., Khoury, H.J., Muller, M.C., Lambert, A., Matloub, Y. & Hochhaus, A. (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 95, 232-240.
81. Sherbenou, D.W., Wong, M.J., Humayun, A., McGreevey, L.S., Harrell, P., Yang, R., Mauro, M., Heinrich, M.C., Press, R.D., Druker, B.J. & Deininger, M.W. (2007) Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia, 21, 489-493.
82. Shima, H., Tokuyama, M., Tanizawa, A., Tono, C., Hamamoto, K., Muramatsu, H., Watanabe, A., Hotta, N., Ito, M., Kurosawa, H., Kato, K., Tsurusawa, M., Horibe, K. & Shimada, H. (2011) Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. Journal of Pediatrics, 159, 676-681.
83. Silver, R.T., Woolf, S.H., Hehlmann, R., Appelbaum, F.R., Anderson, J., Bennett, C., Goldman, J.M., Guilhot, F., Kantarjian, H.M., Lichtin, A.E., Talpaz, M. & Tura, S. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 94, 1517-1536.
84. Sokal, J.E., Baccarani, M., Tura, S., Fiacchini, M., Cervantes, F., Rozman, C., Gomez, G.A., Galton, D.A., Canellos, G.P., Braun, T.J., Clarkson, B.D., Carbonell, F., Heimpel, H., Extra, J.M., Fiere, D., Nissen, N.I., Robertson, J.E. & Cox, E.B. (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood, 66, 1352-1357.
85. Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. & Baccarani, M. (2004) Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clinical Chemistry, 50, 1203-1213.
86. Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., Luatti, S., de Lavallade, A., Cilloni, D., Izzo, B., Fava, M., Abruzzese, E., Alberti, D., Pane, F., Saglio, G. & Baccarani, M. (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. Journal of Clinical Oncology, 23, 4100-4109.
87. Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E., de Matteis, S., Gozzini, A., Iacobucci, I., Palandri, F., Gugliotta, G., Papayannidis, C., Poerio, A., Amabile, M., Cilloni, D., Rosti, G., Baccarani, M. & Martinelli, G. (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 114, 2168-2171.
88. Soverini, S., Hochhaus, A., Nicolini, F.E., Gruber, F., Lange, T., Saglio, G., Pane, F., Muller, M.C., Ernst, T., Rosti, G., Porkka, K., Baccarani, M., Cross, N.C. & Martinelli, G. (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118, 1208-1215.
89. Suttorp, M. & Millot, F. (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology - American Society of Hematology Educational Program, 2010, 368-376.
90. Suttorp, M., Thiede, C., Tauer, J.T., Roettgers, S., Sedlacek, P. & Harbott, J. (2009a) Chronic myeloid leukemia in pediatrics - first results from study CML-PAED II. (Abstract). Blood, 114, 145.
91. Suttorp, M., Claviez, A., Bader, P., Peters, C., Gadner, H., Ebell, W., Dilloo, D., Kremens, B., Kabisch, H., Fuhrer, M., Zintl, F., Gobel, U. & Klingebiel, T. (2009b) Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klinische Padiatrie, 221, 351-357.
92. Vandyke, K., Dewar, A.L., Fitter, S., Menicanin, D., To, L.B., Hughes, T.P. & Zannettino, A.C. (2009) Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23, 2155-2159.
93. Wadhwa, J., Szydlo, R.M., Apperley, J.F., Chase, A., Bua, M., Marin, D., Olavarria, E., Kanfer, E. & Goldman, J.M. (2002) Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood, 99, 2304-2309.
94. Willis, S.G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E.P., McWeeney, S., Kovacs, I., Park, B., Druker, B.J. & Deininger, M.W. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106, 2128-2137.